QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Survodutide?
Survodutide (Dual GLP-1R/GCGR agonist — BI 456906) is a Synthetic fatty acid-conjugated peptide. Dual GLP-1R and glucagon receptor co-agonist (not GIPR). Unlike tirzepatide (GLP-1R+GIPR), survodutide targets GLP-1R+GCGR — the same receptor pairing as the glucagon component of retatrutide. NASH Phase 2b: significant liver fat reduction, NASH resolution. Clinical-stage GCGR+GLP-1R compound.
Research Applications
GLP-1R+GCGR Co-agonism
Distinct from tirzepatide (GLP-1R+GIPR) — GCGR instead of GIPR
GCGR Research
Glucagon receptor activation without GIPR confound
NASH Research
Phase 2b reference compound — liver fat and NASH resolution
Thermogenesis
GCGR-mediated fat oxidation and energy expenditure
Mechanistic Comparison
vs retatrutide (triple) and tirzepatide (different dual)
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized |
| Molecular Formula | Large synthetic peptide (sequence-specific; proprietary) |
| Peptide Type | Dual Glucagon Receptor / GLP-1 Receptor Agonist |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | As indicated by manufacturer |




